$-0.19
(Market cap
$37 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
1.2
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$-846 Mln
-
ROE
-2.5 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
0
-
Debt to Equity
--
-
Book Value
$--
-
EPS
$--
-
Face value
--
-
Shares outstanding
35,312,200
7 Years Aggregate
CFO
Kr.-1,333.66 Mln
EBITDA
Kr.-1,448.03 Mln
Net Profit
Kr.-1,464.79 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Orphazyme A/S - ADR
| -93.8 | -56.6 | -88.1 | -97.3 | -- | -- | -- |
|
BSE Sensex*
| -11.1 | -2.1 | -8.9 | -7.5 | 6.6 | 9.1 | 11.4 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2021
|
|---|---|
|
Orphazyme A/S - ADR
| -77.5 |
|
S&P Small-Cap 600
| 25.3 |
|
BSE Sensex
| 22.0 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Shareholding Pattern
View DetailsAbout Orphazyme A/S - ADR
Orphazyme A/S, a biopharmaceutical company, develops therapies for the treatment of neurodegenerative orphan diseases. The company focuses on the amplification of heat-shock proteins to develop and commercialize therapeutics for diseases caused by... protein misfolding and aggregation, and lysosomal dysfunction, including lysosomal storage and neuromuscular degenerative diseases. Its lead candidate is the Arimoclomol, which is in clinical development for four orphan diseases, including Niemann-Pick disease type C, Amyotrophic Lateral Sclerosis, Inclusion Body Myositis, and Gaucher disease. The company was incorporated in 2009 and is headquartered in Copenhagen, Denmark. Read more
-
CEO & CFO
Mr. Anders Fink Vadsholt M.B.A., M.Sc., MBA
-
CEO & CFO
Mr. Anders Fink Vadsholt M.B.A., M.Sc., MBA
-
Headquarters
Copenhagen
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Orphazyme A/S - ADR
What is the current share price of Orphazyme A/S - ADR Today?
The share price of Orphazyme A/S - ADR is $0.15 (NASDAQ) as of 26-May-2022 09:30 EDT. Orphazyme A/S - ADR has given a return of -97.3% in the last 1 years.
What is the current PB & PE ratio of Orphazyme A/S - ADR?
Since, TTM earnings of Orphazyme A/S - ADR is negative, P/E ratio is not available.
The P/B ratio of Orphazyme A/S - ADR is 1.25 times as on 26-May-2022, a 76 discount to its peers’ median range of 5.14 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2020
|
--
|
--
|
|
2019
|
--
|
--
|
|
2018
|
--
|
--
|
|
2017
|
--
|
--
|
|
2016
|
--
|
--
|
What is the 52 Week High and Low of Orphazyme A/S - ADR?
The 52-week high and low of Orphazyme A/S - ADR are Rs -- and Rs -- as of 17-May-2026.
What is the market cap of Orphazyme A/S - ADR?
Orphazyme A/S - ADR has a market capitalisation of $ 37 Mln as on 26-May-2022. As per SEBI classification, it is a Small Cap company.
Should I invest in Orphazyme A/S - ADR?
Before investing in Orphazyme A/S - ADR, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.